- Business
- EGF Theramed Health Corp. is a Canada-based biotechnology company that develops products, technologies, and diagnostic tools focused on personalized medical care; it conducts research into natural health and wellness products, with an emphasis on psychedelics such as psilocybin for treating mental health conditions including treatment-resistant depression, anxiety, post-traumatic stress disorder, and depression. The company offers biomedical online services for monitoring and treating common health problems; through subsidiaries and portfolio companies, it provides botanical extract extraction and purification technologies, extract formulations, and medical monitoring device technology; its portfolio includes Pharmadelic Labs, which improves and patents engineering processes for the biosynthesis of psilocybin and other compounds; and Green Parrot Labs, a Caribbean-based entity researching psilocybin and establishing health centers for treatment-resistant conditions. Subsidiaries encompass Hemp Extraction Technology Corp., Western Agri Supply Solutions Inc., Medical Green Natural List Corp., and Seedadelic Health Services Corp., supporting operations in health care and life sciences segments targeting consumers seeking personalized wellness solutions. Founded prior to its public listing and headquartered at 609 Granville Street, Suite 1600, Vancouver, British Columbia, V7Y 1C3, Canada, the company operates primarily in Canada with Caribbean extensions via joint ventures and trades on the Canadian Securities Exchange (TMED), OTC Markets (EVAHF), and Frankfurt (AUH/AUHP). Recent developments include a 2020 joint venture and acquisition of a 40% equity interest in Green Parrot Labs Corp. for collaboration on psilocybin and cannabinoid biosynthesis, wellness centers, and medical tourism in Jamaica and the British Virgin Islands; a concurrent non-brokered private placement targeting up to CAD$2 million for business development, marketing, and working capital; shares-for-debt settlements as of July 2024; and ongoing earnings reports, with results for the third quarter and nine months ended March 31, 2025, released in May 2025, alongside a leadership team led by CEO Connor Yuen since August 2022.